Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI France ETF (EWQ) vs Eli Lilly And Co (LLY) Price & Performance

iShares MSCI France ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares MSCI France ETF vs Eli Lilly And Co — how do they compare? iShares MSCI France ETF trades at $45.15, while Eli Lilly And Co trades at $1,176.18 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals.

EWQLLY
Sector
Broad Market / FactorHealth
52-Week High
$48.35$1.24K
52-Week Low
$41.43$625.65
Market Cap
$1.03T
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI France ETF

No Aura AI signal available yet.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.

Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI France ETF

EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.

Read more on EWQ

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY